Quarterly Report

Vir Biotechnology, Inc. Filed 2026-11-04 Acc 0001628280-26-070273

Documents 1

2026-11-06 SCHEDULE 13D/A Beneficial Ownership Report
2026-11-04 10-Q Quarterly Report
2026-11-04 8-K Results of operations
2026-11-04 4 EVP, General Counsel, Corp Sec sold 3,750 shares at an average $11.18 ($41,939)
2026-11-03 144 Sale of Securities
2026-11-02 144 Sale of Securities
2026-08-05 10-Q Quarterly Report

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading vir-20260930.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…